Search

Branchiogenic cysts occuring within the parotid gland are rare developmental anomalies and can be preoperatively misdiagnosed as benign parotid tumors.A 54-year-old female had a painless swelling in the right parotid region. The swelling was elastic hard, nontender, and slightly mobile. It had a smooth surface and was 33×33mm in size. Ultrasonography, CT scan and MRI suggested a benign cystic tumor in the superficial lobe of the parotid gland. A superficial lobectomy of the parotid gland was performed, with care not to injure the facial nerve. Subsequent histopathological examination revealed a branchial cyst.

A 21-year-old female had chondroblastoma arising from the left temporal bone. Although 32 cases of temporal chondroblastoma have been reported, this is the first patient who had facial palsy as the initial symptom. The tumor extended to the dura, so the patient was treated with wide local excision through a combined extended transmastoid and middle cranial fossa approach. The bone defect was found in the horizontal to geniculate ganglia of the facial canal where it compressed the facial nerve. Removal of the tumor cured the facial palsy. This disease should be included in the differential diagnosis of facial palsy.

Banan® (cefpodoxime proxetil CPDX-PR) was administered to 177 patients with infections in the department of otorhinolaryngology, and its clinical and bacteriological effects, and its concentration in tissue and blood were determined.The clinical effect was 90.5% for acute otitis media, 59.0% for chronic otitis media, 92.0% for acute sinusitis, 84.2% for chronic sinusitis, and 88.2% for tonsillitis. The bacteriological bacterial elimination rate was 82.4% for acute otitis media, 62.5% for chronic otitis media, 88.9% for acute sinusitis, 64.7% for chronic sinusitis, and 91.3% for tonsillitis.The concentration of the drug in tissue was 0.25 to 0.70μ/ml, and the concentration in blood was 0.12 to 2.45μg/ml.Side effects were not observed in any of the cases.

We performed clinical and bacteriological studies on Ceftriaxone, (Rocephin®) a broad spectrum antibacterial agent with a long half-life, in the treatment of adult infections of the upper respiratory tract (14 cases of tonsillitis and 20 cases of pharyngolaryngitis).The rate of clinical improvement was 92.8% for tonsillitis and 85.9% for pharyngolaryngitis. In terms of its bacteriological effect, rate of improvement for S. aureus and B. streptococcus was 87.5% and 81.8%, and 100% and 100% for tonsillitis and pharyngolaryngitis, respectively. The blood concentration of Ceftriaxone after a single injection was 169.2, 81.0, 45.1 and 16.8μg/ml at 1, 6, 12 and 24hr, respectively.These results suggest the effectiveness of Ceftriaxone in the treatment of infections of the upper respiratory tract.